Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
Sponsor: Clover Biopharmaceuticals USA, LLC
Summary
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
Official title: A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Tolerability and Immunogenicity of SCB-1019T in Adults Who Were Vaccinated With AREXVY at Least 18 Months Before
Key Details
Gender
All
Age Range
60 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2025-03-21
Completion Date
2026-06-03
Last Updated
2025-05-14
Healthy Volunteers
Yes
Conditions
Interventions
Candidate vaccine, SCB-1019T
SCB-1019T is a novel bivalent recombinant RSV vaccine (CHO Cell) designed to broadly neutralize the two dominant circulating strains of the virus. The SCB-1019T vaccine consists of the PreF protein subunits from the two dominant circulating strains, strain A and strain B, fused to Trimer-Tag™.
AREXVY
positive comparator
placebo
Placebo Comparator
Locations (5)
AMR Phoenix
Phoenix, Arizona, United States
AMR Fort Myers
Fort Myers, Florida, United States
AMR Lexington
Lexington, Kentucky, United States
AMR Kansas City
Kansas City, Missouri, United States
Knoxville
Knoxville, Tennessee, United States